Curis, Inc.  

(Public, NASDAQ:CRIS)   Watch this stock  
Find more results for CRIS
1.67
-0.12 (-6.70%)
After Hours: 1.67 0.00 (0.00%)
Aug 24, 4:47PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.63 - 1.92
52 week 1.25 - 3.18
Open 1.80
Vol / Avg. 670,498.00/280,707.00
Mkt cap 222.43M
P/E     -
Div/yield     -
EPS -0.31
Shares 129.47M
Beta 1.74
Inst. own 53%
Nov 7, 2016
Q3 2016 Curis Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 7, 2016
Curis Inc at Robert W Baird Global Healthcare Conference Add to calendar
Aug 4, 2016
Q2 2016 Curis Inc Earnings Release
Aug 4, 2016
Q2 2016 Curis Inc Earnings Call - Webcast
Jun 8, 2016
Curis Inc at Jefferies Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -672.02% -748.64%
Operating margin -635.71% -716.91%
EBITD margin - -714.87%
Return on average assets -56.81% -74.86%
Return on average equity -88.68% -125.10%
Employees 44 -
CDP Score - -

Address

4 Maguire Rd
LEXINGTON, MA 02421-3112
United States - Map
+1-617-5036500 (Phone)
+1-617-5036501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company's drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.

Officers and directors

James R. McNab Jr. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Ali Fattaey Ph.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Daniel R. Passeri J.D. Vice Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
James E. Dentzer Chief Financial Officer, Chief Administrative Officer, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
Mani Mohindru Ph.D. Senior Vice President, Chief Strategy Officer
Bio & Compensation  - Reuters
David Tuck M.D. Senior Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
Kenneth J. Pienta M.D. Director
Age: 55
Bio & Compensation  - Reuters
Martyn D. Greenacre Independent Director
Age: 73
Bio & Compensation  - Reuters
Kenneth I. Kaitin Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Robert E. Martell M.D., Ph.D. Independent Director
Age: 52
Bio & Compensation  - Reuters